Ken Griffin
GLUE icon

Ken Griffin’s Monte Rosa Therapeutics GLUE Stock Holding History

Ken Griffin’s Portfolio GLUE Stock Details GLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$541K Buy
32,900
+13,400
+69% +$256K ﹤0.01% 9104
2025
Q4 		$306K Sell
19,500
-9,000
-32% -$121K ﹤0.01% 10098
2025
Q3 		$211K Buy
+28,500
New +$151K ﹤0.01% 11156
2025
Q2 		– Sell
-22,400
Closed -$104K – 13457
2025
Q1 		$104K Buy
22,400
+6,500
+41% +$39.9K ﹤0.01% 11403
2024
Q4 		$110K Sell
15,900
-15,300
-49% -$115K ﹤0.01% 11335
2024
Q3 		$165K Buy
31,200
+22,700
+267% +$115K ﹤0.01% 10428
2024
Q2 		$31.8K Buy
8,500
+7,300
+608% +$37.2K ﹤0.01% 12209
2024
Q1 		$8.46K Sell
1,200
-9,800
-89% -$58.1K ﹤0.01% 13551
2023
Q4 		$62.1K Buy
+11,000
New +$43.2K ﹤0.01% 11548
2023
Q1 		– Sell
-1,400
Closed -$10.7K – 14997
2022
Q4 		$10.7K Buy
+1,400
New +$11.7K ﹤0.01% 13608

Other funds holding GLUE

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Ken Griffin's GLUE Position: Q1 2026 in Review

Ken Griffin increased its Monte Rosa Therapeutics (GLUE) stake by 450% in Q1 2026, buying an estimated $3.98M and bringing the position to 254,518 shares worth $4.19M. The position accounts for ﹤0.01% of the portfolio, ranked #4639.

Ken Griffin first reported a position in GLUE in Q2 2021 and has held it in 19 quarters since. The position peaked at $7.79M in Q3 2022. 191 funds tracked by Wall St. Rank hold GLUE as of Q1 2026.

  • Ken Griffin held 254,518 shares of Monte Rosa Therapeutics worth $4.19M as of Q1 2026.
  • Ken Griffin bought 208,255 Monte Rosa Therapeutics shares in Q1 2026, an estimated $3.98M.
  • Monte Rosa Therapeutics made up ﹤0.01% of Ken Griffin's portfolio in Q1 2026, its #4639 holding.
  • Ken Griffin first reported a position in Monte Rosa Therapeutics in Q2 2021 and has held it in 19 quarters since.
  • Ken Griffin's Monte Rosa Therapeutics position peaked at $7.79M in Q3 2022.
  • 191 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.